This undesirable outcome may be attributed to the ability of tumours to acquire resistance to VEGF inhibition, e.g., by the release of more proangiogenic factors, such as angiopoietin 1 (ANGPT1), resulting in increased amounts of vascular progenitor cells [140]. The gene discussed is ANGPT1; the disease is neoplasm.